2015年欧洲肾上腺肿瘤研究网络分期系统(mENSAT):美国验证研究
基于SEER数据库(2004-2020)的858例肾上腺皮质癌(ACC)患者,验证2015年mENSAT对癌症特异性死亡(CSM)和总死亡(OM)的预测能力,并与AJCC第8版比较。mENSAT与AJCC的3年CSM预测准确率几乎相同(74.7% vs 74.5%),但mENSAT校准度低于AJCC,在美国ACC患者中mENSAT相对AJCC无明显获益。
要点
- mENSAT预测3年CSM准确率74.7%,与AJCC的74.5%几乎相同。
- mENSAT预测3年OM准确率73.8%,与AJCC的73.5%几乎相同。
- mENSAT校准度低于AJCC,在美国ACC患者中无明显获益。
核心结论
- mENSAT预测CSM的准确率与AJCC几乎相同(74.7% vs 74.5%),预测OM的准确率也几乎相同(73.7% vs 73.5%)。
- mENSAT的校准度低于AJCC,在美国ACC患者中使用mENSAT相对AJCC无明显获益。
研究设计与样本
- 基于SEER数据库(2004-2020)的大规模当代美国队列,纳入858例ACC患者,验证mENSAT的准确性和校准度,并与AJCC第8版比较。
主要发现
- 在858例ACC患者中,mENSAT预测3年CSM的准确率为74.7%,预测3年OM的准确率为73.8%。
- mENSAT预测CSM的最大偏离理想值为+17.2%,预测OM的最大偏离理想值为+11.8%。
- AJCC预测3年CSM的准确率为74.5%,预测3年OM的准确率为73.5%。
- AJCC预测CSM的最大偏离理想值为-6.7%,预测OM的最大偏离理想值为-7.1%。
临床怎么用
- 作者认为,在美国ACC患者中,使用mENSAT相对AJCC无明显获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test the ability of the 2015 modified version of the European Network for the Study of Adrenal Tumors staging system (mENSAT) in predicting cancer-specific mortality (CSM), as well as overall mortality (OM) in adrenocortical carcinoma (ACC) patients of all stages, in a large-scale, and contemporary United States cohort. METHODS: We relied on the Surveillance, Epidemiology, and End Results (SEER) database (2004-2020) to test the accuracy and calibration of the mENSAT and subsequently compared it to the 8th edition of the American Joint Committee on Cancer staging system (AJCC). RESULTS: In 858 ACC patients, mENSAT accuracy was 74.7% for 3-year CSM predictions and 73.8% for 3-year OM predictions. The maximum departures from ideal predictions in mENSAT were +17.2% for CSM and +11.8% for OM. Conversely, AJCC accuracy was 74.5% for 3-year CSM predictions and 73.5% for 3-year OM predictions. The maximum departures from ideal predictions in AJCC were -6.7% for CSM and -7.1% for OM. CONCLUSION: The accuracy of mENSAT is virtually the same as that of AJCC in predicting CSM (74.7% vs 74.5%) and OM (73.7% vs 73.5%). However, calibration is lower for mENSAT than for AJCC. In consequence, no obvious benefit appears to be associated with the use of mENSAT relative to AJCC in US ACC patients.
引用
- Jannello LMI, Incesu RB, Morra S, et al. The European Network for the Study of Adrenal Tumors Staging System (2015): A United States Validation. J Clin Endocrinol Metab. 2024. PMID: 38266758. doi:10.1210/clinem/dgae047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。